论文部分内容阅读
目的探讨肺表面活性物质预防新生儿呼吸窘迫综合征临床效果。方法我院收治的发生呼吸困难的早产儿60例,平均分为治疗组和对照组各30例。两组患儿均根据病情给予对症处理。对照组患儿仅给予对症治疗,治疗组患儿在对照组基础上均给予固尔苏治疗。结果治疗组患儿给药后6、24、48 h时,PaO2、PaCO2、pH的检测结果均明显优于对照组患儿(P<0.05)。治疗组患儿呼吸窘迫的发生率为10.00%,对照组患儿呼吸窘迫的发生率为43.33%,治疗组患儿的呼吸窘迫发生率明显低于对照组患儿(P<0.05)。随着胎龄的增加,患儿发生呼吸窘迫综合征的比例逐渐下降(P<0.05)。结论肺表面活性物质的应用可以有效的预防新生儿呼吸窘迫综合征的发生,值得临床推广使用。
Objective To investigate the clinical effect of pulmonary surfactant in preventing neonatal respiratory distress syndrome. Methods 60 cases of premature infants with dyspnea admitted to our hospital were divided into treatment group and control group, with an average of 30 cases each. Two groups of children were given symptomatic treatment based on the condition. Children in the control group were given symptomatic treatment only. The children in the treatment group were treated with Guer Su on the basis of the control group. Results At 6, 24 and 48 h after treatment, PaO2, PaCO2 and pH in the treatment group were significantly better than those in the control group (P <0.05). The incidence of respiratory distress was 10.00% in the treatment group and 43.33% in the control group. The incidence of respiratory distress in the treatment group was significantly lower than that in the control group (P <0.05). With the increase of gestational age, the proportion of children with respiratory distress syndrome gradually decreased (P <0.05). Conclusion The application of pulmonary surfactant can effectively prevent neonatal respiratory distress syndrome and is worthy of clinical promotion.